Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04575896 · ClinicalTrials.gov registry record · Phase 4
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04575896: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT04575896 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04575896, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 2 weeks post-renal transplant.
Interventions
- DRUG Glecaprevir/pibrentasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2023-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04575896
The ClinicalTrials.gov registry entry for NCT04575896 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glecaprevir/pibrentasvir is the first listed.
NCT04575896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04575896 about?
NCT04575896 is a clinical study titled "Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors". In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) admini...
What is the current status of trial NCT04575896?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-11-20. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT04575896?
The interventions under investigation include: Glecaprevir/pibrentasvir (DRUG).
Who is sponsoring clinical trial NCT04575896?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.